|
20/12/2019 |
Appendix 3B - AGC |
|
|
20/12/2019 |
Termination of AGC Agreement paves way for commercial partner |
|
|
18/12/2019 |
Regeneus receives innovation grant |
|
|
21/11/2019 |
Results of 2019 Annual General Meeting |
|
|
21/11/2019 |
CEO Presentation to 2019 Annual General Meeting |
|
|
21/11/2019 |
Chairman's Address to Shareholders |
|
|
20/11/2019 |
Cleansing Statement |
|
|
20/11/2019 |
Appendix 3B |
|
|
19/11/2019 |
Japanese Biotech Fund takes up all Rights Issue Shortfall |
|
|
31/10/2019 |
Appendix 4C Query and Response |
|
|
31/10/2019 |
Appendix 4C - Quarterly |
|
|
30/10/2019 |
Appendix 4G and Corporate Governance Statement |
|
|
30/10/2019 |
Annual Report 2019 |
|
|
18/10/2019 |
Notice of Annual General Meeting / Proxy Form |
|
|
15/10/2019 |
Regeneus receives A$1.5 million in R&D Tax Incentives |
|
|
15/10/2019 |
Change of Registered Office and Principal Place of Business |
|
|
11/09/2019 |
Form 603 - Notice of substantial holder - Leo Lee |
|
|
11/09/2019 |
Change of interests of substantial holder - Graham Vesey |
|
|
10/09/2019 |
Date of AGM |
|
|
03/09/2019 |
Appendix 3Y - Glen Richards |
|
|
03/09/2019 |
Appendix 3Y - Leo Lee |
|
|
03/09/2019 |
Appendix 3B |
|
|
30/08/2019 |
Appendix 4E - Preliminary final report for the year ended 30 June 2019 |
|
|
30/08/2019 |
Clarification to announcement |
|
|
30/08/2019 |
Rights Issue Shortfall |
|
|
13/08/2019 |
Entitlement Offer - Confirmation of despatch of Entitlement Offer Booklet |
|
|
13/08/2019 |
Restructuring results in 50% reduction in operating costs |
|
|
07/08/2019 |
Appendix 3B and Cleansing Statement |
|
|
07/08/2019 |
Rights Issue Investor Presentation |
|
|
02/08/2019 |
Regeneus Entitlement Offer - Notice to Shareholders |
|
|
01/08/2019 |
Regeneus Entitlement Offer - Notice to Option Holders |
|
|
01/08/2019 |
Regeneus: Cleansing Notice |
|
|
01/08/2019 |
Appendix 3B: New issue announcement, application for quotation of additional securities and agreement |
|
|
01/08/2019 |
Offer Booklet |
|
|
01/08/2019 |
Rights Issue Investor Presentation |
|
|
01/08/2019 |
Capital Raise up to $5.5 million supports Progenza commercialisation strategy |
|
|
30/07/2019 |
Market Announcement: Regeneus - Trading Halt |
|
|
23/07/2019 |
Positive preclinical trial results for Progenza in treating neuropathic pain |
|
|
22/07/2019 |
New Strategy To Deliver Therapies For Global Pain Market |
|
|
02/05/2019 |
Appendix 3X - Initial Director's Interest Notice |
|
|
02/05/2019 |
Appendix 3Z - Final Director's Interest Notice |
|
|
29/04/2019 |
Appointment of industry leaders to Regeneus Board provide foundation for global growth rollout |
|
|
28/02/2019 |
Directors Provide $2.5M Loan to Extend Funding Runway |
|
|
22/02/2019 |
Response to ASX Appendix 4C Query Letter |
|
|
01/02/2019 |
Material Terms of Contract for Chief Executive Officer |
|
|
30/01/2019 |
Quarterly results for the period ended 31 December 2018 |
|
|
23/01/2019 |
New CEO Appointed to Accelerate Global Growth |
|